m6A-centered Drug Response Information

General Information of the Drug (ID: M6ADRUG0152)
Name
FB23-2
Synonyms
2243736-45-8, FB23-2, 2-((2,6-Dichloro-4-(3,5-dimethylisoxazol-4-yl)phenyl)amino)-N-hydroxybenzamide, 2-[2,6-dichloro-4-(3,5-dimethyl-1,2-oxazol-4-yl)anilino]-N-hydroxybenzamide, FB23-2(FTO Demethylase inhibitor FB23-2), CHEMBL4567838, SCHEMBL23261120, BDBM589237, GLXC-25980, BCP31164, EX-A3403, US11555009, Compound 25, MFCD32174281, s8837, AKOS040759087, AC-36448, DA-73314, MS-26546, HY-127103, CS-0093102, D81008, FB23-2(FTO Demethylase inhibitor FB23-2), FB-23-2; FB 23-2; FB232; FB-232; FB 232, 2-{[2,6-Dichloro-4-(3,5-dimethyl-1,2-oxazol-4-yl)phenyl]amino}-N-hydroxybenzamide
    Click to Show/Hide
Structure
3D MOL
2D MOL
Formula
C18H15CL2N3O3
InChI
InChI=1S/C18H15Cl2N3O3/c1-9-16(10(2)26-23-9)11-7-13(19)17(14(20)8-11)21-15-6-4-3-5-12(15)18(24)22-25/h3-8,21,25H,1-2H3,(H,22,24)
InChIKey
ILHNIWOZZKIBNW-UHFFFAOYSA-N
PubChem CID
138454779
Full List of Crosstalk(s) between m6A Modification and Epigenetic Regulation Related to This Drug
In total 2 item(s) under this drug
Crosstalk ID: M6ACROT03086
 Crosstalk Info 
m6A Regulator Fat mass and obesity-associated protein (FTO)
 Regulator Info 
m6A Target Cyclin-dependent kinase 2 (CDK2)
 Target Gene 
Epigenetic Regulator Histone acetyltransferase p300 (P300)
Regulated Target Histone H3 lysine 18 lactylation (H3K18la)
Crosstalk relationship Histone modification → m6A
Disease Diabetic retinopathy
 Disease Info 
Crosstalk ID: M6ACROT03087
 Crosstalk Info 
m6A Regulator YTH domain-containing family protein 2 (YTHDF2)
 Regulator Info 
m6A Target Cyclin-dependent kinase 2 (CDK2)
 Target Gene 
Epigenetic Regulator Histone acetyltransferase p300 (P300)
Regulated Target Histone H3 lysine 18 lactylation (H3K18la)
Crosstalk relationship Histone modification → m6A
Disease Diabetic retinopathy
 Disease Info 
References
Ref 1 Interferon-beta gene therapy for cancer: basic research to clinical application. Cancer Sci. 2004 Nov;95(11):858-65. doi: 10.1111/j.1349-7006.2004.tb02194.x.
Ref 2 Polyamines and the NMDA receptor: modifying intrinsic activities with aromatic substituents. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2837-41. doi: 10.1016/j.bmcl.2006.03.015. Epub 2006 Mar 24.
Ref 3 GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. Transl Lung Cancer Res. 2020 Oct;9(5):2008-2015. doi: 10.21037/tlcr-20-608.
Ref 4 US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion.